How EOM Pharmaceutical Holdings is positioning EOM613 as a potential multi-cytokine therapy for cancer cachexia
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
Why CUE-401’s IMMUNOLOGY2026 data could matter for autoimmune drug pipelines
Cue Biopharma, Inc. unveils new CUE-401 data. Find out what this means for autoimmune therapy development and the regulatory path ahead.
Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?
Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.
Meiji Seika Pharma initiates ME3241 Phase I study, inverting checkpoint blockade logic for autoimmune therapy
Meiji Seika Pharma initiates Phase I of ME3241, a PD-1 agonist antibody for autoimmune disease in Australia. Read the clinical analysis.